{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:49:19Z","timestamp":1761562159944,"version":"3.37.3"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"suppl 3","funder":[{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","award":["R56 AI111985"],"award-info":[{"award-number":["R56 AI111985"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Infect Dis."],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.1093\/cid\/ciw472","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T03:18:14Z","timestamp":1476415094000},"page":"S75-S79","source":"Crossref","is-referenced-by-count":14,"title":["A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground"],"prefix":"10.1093","volume":"63","author":[{"given":"Shashikant","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devyani","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jotam G.","family":"Pasipanodya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumya","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Nuermberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"issue":"suppl 1","key":"2016101400180352000_63.suppl_3.S75.1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5588\/ijtld.15.0418","article-title":"Childhood tuberculosis in the United States: shifting the focus to prevention","volume":"19","author":"Cruz","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2016101400180352000_63.suppl_3.S75.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1008049"},{"key":"2016101400180352000_63.suppl_3.S75.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60195-1"},{"key":"2016101400180352000_63.suppl_3.S75.4","doi-asserted-by":"publisher","DOI":"10.1057\/jphp.2014.35"},{"key":"2016101400180352000_63.suppl_3.S75.5","unstructured":"International Union Against Tuberculosis and Lung Disease. Desk-guide for diagnosis and management of TB in children. Paris: The Union, 2014."},{"key":"2016101400180352000_63.suppl_3.S75.6","doi-asserted-by":"crossref","unstructured":"Rogers Z , Hiruy H , Pasipanodya J et al . The non-linear child: ontogeny, isoniazid concentration, and NAT2 gene interactions modulate enzyme reaction kinetics and metabolism. EBioMedicine 2016. Available at: http:\/\/dx.doi.org\/10.1016\/j.ebiom.2016.07.031. Accessed 2016.","DOI":"10.1016\/j.ebiom.2016.07.031"},{"issue":"suppl 3","key":"2016101400180352000_63.suppl_3.S75.7","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2016101400180352000_63.suppl_3.S75.8","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.142"},{"key":"2016101400180352000_63.suppl_3.S75.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035092"},{"key":"2016101400180352000_63.suppl_3.S75.10","first-page":"761","article-title":"Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol","volume":"97","author":"Sutherland","year":"1959","journal-title":"AMA J Dis Child"},{"key":"2016101400180352000_63.suppl_3.S75.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196004212621601"},{"key":"2016101400180352000_63.suppl_3.S75.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00226-1"},{"key":"2016101400180352000_63.suppl_3.S75.13","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200012000-00012"},{"key":"2016101400180352000_63.suppl_3.S75.14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ425"},{"key":"2016101400180352000_63.suppl_3.S75.15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv183"},{"key":"2016101400180352000_63.suppl_3.S75.16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ427"},{"key":"2016101400180352000_63.suppl_3.S75.17","doi-asserted-by":"publisher","DOI":"10.2174\/138161211797470192"},{"key":"2016101400180352000_63.suppl_3.S75.18","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-09"},{"key":"2016101400180352000_63.suppl_3.S75.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.02.040"},{"key":"2016101400180352000_63.suppl_3.S75.20","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02565-14"},{"key":"2016101400180352000_63.suppl_3.S75.21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01370-01315"},{"key":"2016101400180352000_63.suppl_3.S75.22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3937"},{"key":"2016101400180352000_63.suppl_3.S75.23","first-page":"173","article-title":"Species differences in the pharmacokinetic parameters of cytochrome P450 probe substrates between experimental animals, such as mice, rats, dogs, monkeys, and microminipigs, and humans","volume":"5","author":"Sakai","year":"2014","journal-title":"J Drug Metab Toxicol"},{"key":"2016101400180352000_63.suppl_3.S75.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1744-7348.1939.tb06990.x"},{"issue":"suppl 3","key":"2016101400180352000_63.suppl_3.S75.25","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/cid\/ciw473","article-title":"Concentration-dependent synergy and antagonism of linezolid and moxifloxacin in the treatment of childhood tuberculosis: the dynamic duo","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2016101400180352000_63.suppl_3.S75.26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00763-10"},{"key":"2016101400180352000_63.suppl_3.S75.27","doi-asserted-by":"publisher","DOI":"10.2307\/2280232"},{"key":"2016101400180352000_63.suppl_3.S75.28","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.13-22.2001"},{"key":"2016101400180352000_63.suppl_3.S75.29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu610"},{"key":"2016101400180352000_63.suppl_3.S75.30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00749-10"},{"key":"2016101400180352000_63.suppl_3.S75.31","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2656"},{"key":"2016101400180352000_63.suppl_3.S75.32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2675"},{"key":"2016101400180352000_63.suppl_3.S75.33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00976-12"},{"key":"2016101400180352000_63.suppl_3.S75.34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ426"},{"key":"2016101400180352000_63.suppl_3.S75.35","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit352"},{"key":"2016101400180352000_63.suppl_3.S75.36","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03931-14"},{"issue":"suppl 3","key":"2016101400180352000_63.suppl_3.S75.37","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/ciw482","article-title":"Linezolid for infants and toddlers with disseminated tuberculosis: first steps","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"2016101400180352000_63.suppl_3.S75.38","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciw474","article-title":"A faropenem, linezolid, and moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME path on the Milky Way","volume":"63","author":"Deshpande","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"2016101400180352000_63.suppl_3.S75.39","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1093\/cid\/ciw483","article-title":"Optimal clinical doses of faropenem, linezolid, and moxifloxacin in children with disseminated tuberculosis: Goldilocks","volume":"63","author":"Srivastava","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/63\/suppl_3\/S75\/7935993\/ciw472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T22:03:18Z","timestamp":1503612198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article-lookup\/doi\/10.1093\/cid\/ciw472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":39,"journal-issue":{"issue":"suppl 3","published-online":{"date-parts":[[2016,10,14]]},"published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["10.1093\/cid\/ciw472"],"URL":"https:\/\/doi.org\/10.1093\/cid\/ciw472","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"type":"print","value":"1058-4838"},{"type":"electronic","value":"1537-6591"}],"subject":[],"published":{"date-parts":[[2016,10,14]]}}}